Vnitr Lek 2017, 63(12):987-997 | DOI: 10.36290/vnl.2017.179

Remission of steroid-resistant Still's disease treated with anakinra, evidenced by FDG-PET/CT examination: case report

Zdeněk Adam1, Jana Skřičková2, Milan Krtička3, Zdeněk Řehák4,5, Renata Koukalová4, Andrea Šprláková6, Marta Krejčí1, Luděk Pour1,*, Zdenka Adamová7, Eva Pourová8, Zdeněk Král1
1 Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice
2 Klinika nemocí plicních a TBC LF MU a FN Brno, pracoviště Bohunice
3 Klinika úrazové chirurgie LF MU a FN Brno, pracoviště Bohunice
4 Oddělení nukleární medicíny MOÚ, Brno
5 Regionální centrum molekulární onkologie (RECAMO) MOÚ, Brno
6 Klinika radiologie a nukleární medicíny LF MU a FN Brno, pracoviště Bohunice
7 Ordinace pro děti a dorost, Obilní trh, Brno
8 Ordinace praktického lékaře pro dospělé, Pustiměř u Vyškova

After elimination of infectious causes, neoplastic causes and the systemic autoimmune disease of connective tissue, a patient with high fevers over 39 °C was diagnosed with Still's disease. High doses of prednisone led to resolution of symptoms, however after reducing the doses of prednisone to 15 mg, high fevers over 39 °C returned, as well as joint pains. The high doses of prednisone led to decompensation of diabetes mellitus even with 4 daily insulin dosages. Therefore it was proceeded to regular subcutaneous administration of anakinra once a day. Anakinra enabled the reduction of prednisone to as much as the currently administered 2.5 mg a day, but it has not so far allowed for removing glucocorticoids from the treatment completely. Activity of the disease is shown by the findings within the FDG-PET/CT examination. At the time of maximum activity of the disease there was distinct lymphadenopathy with pathological accumulation of FDG visible as well as increased accumulation of FDG in the hematopoietic bone marrow. As the disease activity decreased, the size of nodules regressed and FDG accumulation in both the lymphatic nodes and bone marrow declined. FDG-PET/CT is a suitable method for monitoring the activity of Still's disease.

Keywords: anakinra; Adult-onset Still's disease

Received: July 18, 2017; Accepted: October 9, 2017; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Skřičková J, Krtička M, Řehák Z, Koukalová R, Šprláková A, et al.. Remission of steroid-resistant Still's disease treated with anakinra, evidenced by FDG-PET/CT examination: case report. Vnitr Lek. 2017;63(12):987-997. doi: 10.36290/vnl.2017.179.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schneider T, Loddenkemper C, Rudwaleit M et al. Horečka nejasného původu v 21. století. Část 2: Neinfekční onemocnění. Medicína po promoci 2006; 7(3): 50-54.
    2. Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 295-298. Dostupné z DOI: <http://dx.doi.org/10.7861/clinmedicine.15-3-295>. Go to original source... Go to PubMed...
    3. Król P, Doležalová P. Horečka jako hlavní projev nemoci. Pediatrie pro praxi 2011; 12(2): 111-114.
    4. Doležalová P, Król P. Recidivující horečky u dětí. Vox pediatrie 2010; 10(3): 16-20.
    5. Tomíčková D. Horečka neznámého původu. Lékařské listy 2009; 58(8): 9-11.
    6. Křivanová A, Adam Z, Mayer J et al. Teplota nejasné etiologie: příčiny a diagnostický postup. Vnitř Lék 2007; 53(2): 169-178. Go to PubMed...
    7. Solav SV. FDG PET/CT in evaluation of pyrexia of unknown origin. Clin Nucl Med 2011; 36(8): e81-e86. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0b013e31821c99b2>. Go to original source... Go to PubMed...
    8. Kaya A, Ergul N, Kaya SY et al. The management and the diagnosis of fever of unknown origin. Expert Rev Anti Infect Ther 2013; 11(8): 805-815. Dostupné z DOI: <http://dx.doi.org/10.1586/14787210.2013.814436>. Go to original source... Go to PubMed...
    9. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19(3): 424-430. Go to PubMed...
    10. Fautrel B, Zing E, Golmard JL et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine 2002; 81(3): 194-200. Go to original source... Go to PubMed...
    11. Bywaters EG. Still's disease in the adult. Annals Rheumatic Diseases 1971; 30(2): 121-133. Go to original source... Go to PubMed...
    12. Owlia M, Mehrpoor G. Adult onset still's disease: a review. Indian J Med Sci 2009; 63(5): 207-221. Dostupné z DOI: <http://dx.doi.org/10.4103/0019-5359.53169>. Go to original source... Go to PubMed...
    13. Cagatay Y, Gul A, Cagatay A et al. Adult-onset still's disease. Int J Clin Pract 2009; 63(7): 1050-1055. Go to original source... Go to PubMed...
    14. Komiya A, Matsui T, Nogi S et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still's disease. Scand J Rheumatol 2012; 41(2): 156-158. Dostupné z DOI: <http://dx.doi.org/10.3109/03009742.2011.644325>. Go to original source... Go to PubMed...
    15. Chen DY, Lan JL, Lin FJ et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004; 31(11): 2189-2198. Go to PubMed...
    16. Arlet JB, Boutin-Le D, Thi Huong J et al. Current concepts on the pathogenesis of adult-onset Still's disease. Rev Med Interne 2005; 26(7): 549-556. Go to original source... Go to PubMed...
    17. Guilpain P, Le Quellec A. About the complexity of adult onset Still's disease…and advances still required for its management. BMC Med 2017; 15(1): 5. Dostupné z DOI: <http://dx.doi.org/10.1186/s12916-016-0769-1>. Go to original source... Go to PubMed...
    18. Girard C, Rech J, Brown M et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology (Oxford) 2016; 55(12): 2237-2247. Go to original source... Go to PubMed...
    19. Ruscitti P, Cipriani P, Ciccia F et al. H-ferritin and CD68(+)/H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. Clin Exp Immunol 2016; 186(1): 30-38. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12826>. Go to original source... Go to PubMed...
    20. Inoue N, Shimizu M, Tsunoda S et al. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol 2016; 169: 8-13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2016.05.010>. Go to original source... Go to PubMed...
    21. Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 2015; 159(1): 72-83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2015.04.018>. Go to original source... Go to PubMed...
    22. Colafrancesco S, Priori R, Valesini G Presentation and diagnosis of adult-onset Still's disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol 2015; 11(6): 749-761. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1037287>. Go to original source... Go to PubMed...
    23. Skácelová M, Horák P. Stillova choroba dospělých. Postgraduální medicína 2015; 17(4): 391-394.
    24. Jarošová K. Kazuistika dospělé pacientky se Stillovou chorobou léčené anakinrou. Farmakoterapie 2012; 8(Suppl 1): 10-11.
    25. Skácelová M, Horák P. Stillova nemoc dospělých - kazuistika. Česká revmatologie 2012; 20(4): 198-202.
    26. Houzarová A. Stillova nemoc. Referátový výběr z revmatologie. 2007; 47(3): 1214-1220. Go to original source...
    27. Jarošová K. Stillova choroba v dospělosti. Česká revmatologie 2006; 14(4): 159-163.
    28. Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 295-298. Dostupné z DOI: <http://dx.doi.org/10.7861/clinmedicine.15-3-295>. Go to original source... Go to PubMed...
    29. Cagatay Y, Gul A, Cagatay A et al. Adult-onset still's disease. Intern J Clin Practice 2009; 63(7): 1050-1055. Go to original source... Go to PubMed...
    30. Mert A, Ozaras R, Tabak F et al. Fever of unknown origin: a review of 20 patients with adult-onset Still's disease. Clin Rheumatol 2003; 22(2): 89-93. Go to original source... Go to PubMed...
    31. Chen DY, Lan HC, Hsieh TY et al. Crico-thyroid perichondritis leading to sore throat in patients with active adult-onset Still's disease. Ann Rheum Dis 2007; 66(9): 1264-1266. Go to original source... Go to PubMed...
    32. Cetkovská P, Benáková N. Autoinflamatorní syndromy s kožními projevy. Česko-slov Derm 2015; 90(4): 144-155.
    33. Mehrpoor G, Owlia M, Soleimani H et al. Adult-onset Still's disease: a report of 28 cases and review of the literature. Modern Rheumatol 2008; 18(5): 480-485. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165-008-0104-6>. Go to original source... Go to PubMed...
    34. Kojima M, Nakamura S, Miyawaki S et al. Lymph node lesion in adult-onset still's disease resembling peripheral T-cell lymphoma: a report of three cases. Intern J Surgical Pathology 2002; 10(3): 197-202. Go to original source... Go to PubMed...
    35. Dong MJ, Wang CQ, Zhao K et al. 18F-FDG PET/CT in patients with adult-onset Still's disease. Clin Rheumatol 2015; 34(12): 2047-2056. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-015-2901-6>. Go to original source... Go to PubMed...
    36. Roy SG, Karunanithi S, Dhull VS et al. <sup>1</sup>⁸F-FDG PET/CT aids the diagnosis of adult onset Still's disease in a patient with fever of unknown origin. Rev Esp Med Nucl Imagen Mol 2014; 33(6): 392-393. Dostupné z DOI: <http://dx.doi.org/10.1016/j.remn.2014.03.001>. Go to original source... Go to PubMed...
    37. Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93(2): 91-99. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000000021>. Go to original source... Go to PubMed...
    38. Yamashita H, Kubota K, Takahashi Y et al. Clinical value of <sup>1</sup>⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature. Mod Rheumatol 2014; 24(4): 645-650. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2013.850998>. Go to original source... Go to PubMed...
    39. Cai L, Chen Y, Huang Z. Elevated FDG activity in lymph nodes as well as the spleen and liver in a patient with adult-onset still disease. Clin Nucl Med 2012; 37(10): 1009-1010. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0b013e31826386d2>. Go to original source... Go to PubMed...
    40. de Graaff LC, ten Broek MR, Schweitzer DH. Is Still's disease still one disease? A case of Adult-onset Still's disease showing accumulation in the carotids and the large vessels of the legs on positron emission tomography: CT images. Rheumatol Int 2012; 32((8): 2487-2490. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-011-1991-y>. Go to original source... Go to PubMed...
    41. Choe JY, Chung DS, Park SH et al. Clinical significance of <sup>1</sup>⁸F-fluoro-dexoxyglucose positron emission tomography in patients with adult-onset Still's disease: report of two cases and review of literatures. Rheumatol Int 2010; 30(12): 1673-1676. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-009-1137-7>. Go to original source... Go to PubMed...
    42. Funauchi M, Ikoma S, Kishimoto K et al. A case of adult onset Still's disease showing marked accumulation in the liver and spleen, on positron emission tomography-CT images. Rheumatol Int 2008; 28(10): 1061-1064. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-008-0562-3>. Go to original source... Go to PubMed...
    43. Chvojka J, Kroužecký A, Raděj J et al. 24letý muž s horečkami, multiorgánovou dysfunkcí a rychle progredujícím ARDS. Vnitř Lék 2009; 55(10): 991-994. Go to PubMed...
    44. Tomš J, Soukup T, Polák J et al. Multiorgánové selhání a syndrom aktivovaných makrofágů u Stillovy nemoci v dospělosti. Česká revmatologie 2012; 20(3): 115-119 (e133-e137).
    45. Kočan L, Vašková J, Vaško L et al. Ťažký priebeh Stillovej choroby s multiorgánovým zlyhávaním a závažnou pečeňovou dysfunkciou. Anest Intenziv Med 2011; 22(6): 337-342.
    46. Tristano EG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008; 14(3): 27-36.
    47. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15(5): 587-590. Go to original source... Go to PubMed...
    48. Kelly J, Chowienczyk M, Gibson T. Sore throat and hyperferritinaemia. J R Soc Med 2001; 94(8): 400-401. Go to original source... Go to PubMed...
    49. Meijvis SCA, Endeman H, Geers AB et al. Extremely high serum ferritin levels as diagnosis tool in adult-onset Still's disease. Neth J Med 2007; 65(6): 212-214.
    50. Fardet, L, Coppo P, Kettaneh A et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008; 58(5): 1521-1527. Dostupné z DOI: <http://dx.doi.org/10.1002/art.23415>. Go to original source... Go to PubMed...
    51. Efthimiou F, Paik FK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheumatic Dis 2006; 65(5): 564-572. Go to original source... Go to PubMed...
    52. Padeh H. Periodic fever syndromes. Pediatr Clin North Am 2005; 52(2): 577-609. Go to original source... Go to PubMed...
    53. Šedivá A, Maňásek V, Gřegořová A et al. Familiární středomořská horečka v České republikace. Vnitř Lék 2014; 60(1): 25-29. Go to PubMed...
    54. Šedivá A, Horváth R, Maňásek V et al. Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic. Clin Genet 2014; 86(6): 564-569. Dostupné z DOI: <http://dx.doi.org/10.1111/cge.12323>. Go to original source... Go to PubMed...
    55. Toplak N, Dolezalovà P, Constantin T et al. [Eastern/Central European autoinflammatory collaborating group for the Paediatric Rheumatology International Trials Organization (PRINTO) and Eurofever Project]. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J 2010; 8: 29. Dostupné z DOI: <http://dx.doi.org/10.1186/1546-0096-8-29>. Go to original source... Go to PubMed...
    56. Vannucci G, Cantarini L, Giani T et al. Glucocorticoids in the management of systemic juvenile idiopathic arthritis. Paediatr Drugs 2013; 15(5): 343-349. Dostupné z DOI: <http://dx.doi.org/10.1007/s40272-013-0038-0>. Go to original source... Go to PubMed...
    57. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still's disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30(2): 222-238. Dostupné z DOI: <http://dx.doi.org/10.1016/j.berh.2016.08.003>. Go to original source... Go to PubMed...
    58. Okamoto O, Oishi M, Fujiwara S. Steroid-resistant adult-onset Still's disease which showed a quick response to methotrexate. J Dermatol 2008; 35(2): 106-110. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1346-8138.2008.00424.x>. Go to original source... Go to PubMed...
    59. Jung JH, Jun JB, Yoo DH et al. High toxicity of sulfasalazine in adult-onset Still's disease. Clin Exp Rheumatol 2000; 18(2): 245-248. Go to PubMed...
    60. Šedivá A, Slíva J, Doležalová P et al. Anakinra. Farmakoterapie 2011; 7(6): 621-629.
    61. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with Anakinra. Ann Rheum Dis 2005; 64(4): 647-648. Go to original source... Go to PubMed...
    62. Kötter I, Wacker A, Koch S et al. Anakinra in patients with treatment-resistant adult-onset still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007; 37(3): 189-197. Go to original source... Go to PubMed...
    63. Jamilloux J, Gerfaud-Valentin M, Henry T et al. Treatment of adult-onset Still's disease: a review. Ther Clin Risk Manag 2014; 11: 33-43. Dostupné z DOI: <http://dx.doi.org/10.2147/TCRM.S64951>. Go to original source... Go to PubMed...
    64. Parisi F, Paglionico A, Varriano V et al. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra. Medicine (Baltimore) 2017; 96(24): e6656. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000006656>. Go to original source... Go to PubMed...
    65. Proft F, Fleck M, Fiehn C et al. Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases: Experiences from a German registry (GRAID2). Z Rheumatol 2017. Dostupné z DOI: <http://dx.doi.org/10.1007/s00393-017-0329-x>. Go to original source... Go to PubMed...
    66. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still's disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30(2): 222-238. Dostupné z DOI: <http://dx.doi.org/10.1016/j.berh.2016.08.003>. Go to original source... Go to PubMed...
    67. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore) 2015; 94(39): e1554. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001554> Go to original source... Go to PubMed...
    68. Waghmare S, Valecka B, Cairns AP. A severe case of adult onset Still disease with myoperikarditis resistant do treatment with tocilizumab but responsive to anakinra. Ulster Med J 2015; 84(2): 130-132. Go to PubMed...
    69. Cavalli G, Franchini S, Aiello P et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol 2015; 44(4): 309-314. Dostupné z DOI: <http://dx.doi.org/10.3109/03009742.2014.992949>. Go to original source... Go to PubMed...
    70. Hong D, Yang Z, Han S et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 2014; 8: 2345-2357. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S73428>. Go to original source... Go to PubMed...
    71. Yilmaz S, Cinar M, Simsek I et al. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease. Mod Rheumatol 2014; 24(6): 1030-1031. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2013.854437>. Go to original source... Go to PubMed...
    72. Al-Homood IA. Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford) 2014; 53(1): 32-38. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket250>. Go to original source... Go to PubMed...
    73. Giampietro C, Ridene M, Lequerre T et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 2013; 65(5): 822-8226. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21901>. Go to original source... Go to PubMed...
    74. Nordström D, Knight A, Luukkainen R et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012; 39(10): 2008-2011. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.111549>. Go to original source... Go to PubMed...
    75. Lahiri M, Teng GG. A case of refractory adult-onset Still's disease treated with anakinra. Int J Rheum Dis 2010; 13(3): e36-e41. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1756-185X.2010.01474.x>. Go to original source... Go to PubMed...
    76. Moulis G, Sailler L, Astudillo L et al. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol 2010; 29(10): 1199-1200. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-010-1459-6>. Go to original source... Go to PubMed...
    77. Ilowite NT, Prather K, Lokhnygina Y et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66(9): 2570-2579. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38699>. Go to original source... Go to PubMed...
    78. Mitha E, Schumacher HR, Fouche L et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013; 52(7): 1285-1292. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket114>. Go to original source... Go to PubMed...
    79. Lovell DJ, Giannini EH, Reiff AO et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013; 65(9): 2486-2496. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38042>. Go to original source... Go to PubMed...
    80. Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 2012; 71(12): 2056-2057. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012-201409>. Go to original source... Go to PubMed...
    81. Krause K, Weller K, Stefaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67(7): 943-950. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398-9995.2012.02843.x>. Go to original source... Go to PubMed...
    82. Schumacher HR Jr, Evans RR, Saag KG et al. Rilonacept (interleukin-1 trap) for revention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64(10): 1462-1470. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21690>. Go to original source... Go to PubMed...
    83. Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71(5): 639-641. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2125.2011.03958.x>. Go to original source... Go to PubMed...
    84. Kone-Paut I, Quartier P, Fain O et al. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care Res (Hoboken) 2017; 69(6): 903-911. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.23083>. Go to original source... Go to PubMed...
    85. Barsotti S, Neri R, Iacopetti V et al. Successful treatment of refractory adult-onset Still disease with canakinumab: a case report. J Clin Rheumatol 2014; 20(2): 121. Dostupné z DOI: <http://dx.doi.org/10.1097/RHU.0000000000000082>. Go to original source... Go to PubMed...
    86. Lo Gullo A, Caruso A, Pipitone N et al. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine 2014; 81(4): 376-377. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2013.12.011>. Go to original source... Go to PubMed...
    87. Perez-Ruiz F, Chinchilla SP, Herrero-Beites AM. Canakinumab for gout: a specific, patient-profiled indication. Expert Rev Clin Immunol 2014; 10(3): 339-347. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2014.880653>. Go to original source... Go to PubMed...
    88. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in the biologic age. Rheum Dis Clin North Am 2013; 39(4): 751-766. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rdc.2013.05.004>. Go to original source... Go to PubMed...
    89. Banse C, Vittecoq O, Benhamou Y et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 2013; 80(6): 653-655. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2013.04.011>. Go to original source... Go to PubMed...
    90. Vandemergel X, Vandergheynst F. Efficacy of low-dose tocilizumab on relapsing adult-onset still's disease. Acta medica (Hradec Králové) 2016; 59(1): 22-25. Dostupné z DOI: <http://dx.doi.org/10.14712/18059694.2016.51>. Go to original source... Go to PubMed...
    91. Cipriani P, Ruscitti P, Carubbi F et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 2014; 33(1): 49-55. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-013-2381-5>. Go to original source... Go to PubMed...
    92. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014; 66(6): 1659-1665. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38398>. Go to original source... Go to PubMed...
    93. Nishina N, Kaneko Y, Kameda H et al. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study. Mod Rheumatol 2015; 25(3): 401-404. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2014.973659>. Go to original source... Go to PubMed...
    94. Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al. Adult-onset Still's disease. Autoimmun Rev 2014; 13(7): 708-722. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2014.01.058>. Go to original source... Go to PubMed...
    95. Suematsu R, Ohta A, Matsuura E et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2012; 22(5): 712-719. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165-011-0569-6>. Go to original source... Go to PubMed...
    96. Maeshima K, Ishii K, Iwakura M et al. Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol 2012; 22(): 137-141. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165-011-0477-9>. Go to original source...
    97. Babacan T, Onat AM, Pehlivan Y et al. Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab. Clin Rheumatol 2010; 29(4): 423-426. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-009-1331-8>. Go to original source... Go to PubMed...
    98. Thonhofer R, Soleiman A, Kriessmayr M et al. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNF alpha therapy. Scand J Rheumatol 2006; 35(6): 485-488. Go to original source... Go to PubMed...
    99. Huffstutter JE, Sienknecht CW. Treatment of resistant adult still disease with infliximab: a report of 2 cases. J Clin Rheumatol 2004; 10(4): 218-221. Go to original source... Go to PubMed...
    100. Dilhuydy MS, Vatan R, Etienne G et al. Prolonged efficacy of infliximab for refractory adult-onset Still's disease. Clin Exp Rheumatol 2005; 23(1): 121-122.
    101. Fautrel B, Sibilia J, Mariette X et al. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64(2): 262-266. Go to original source... Go to PubMed...
    102. Ito T, Ozaki Y, Shimamoto K et al. Successful treatment with plasma exchange in adult-onset Still's disease with hyper-IL-18-naemia and hyperallergic state. Modern Rheumatol 2008; 18(4): 407-410. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165-008-0065-9>. Go to original source... Go to PubMed...
    103. Mahmud H, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol 1999; 26(9): 2067-2068. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.